Toward the Development of a Commercial Process to Produce Muvalaplin. Part II: Preparation of the Drug Substance
- 22 September 2026
- journal article
- Published by American Chemical Society (ACS) in Organic Process Research & Development
- Vol. 30 (10) , 2850-2866
Abstract
Herein, we describe the development of steps 5–7 for a large-scale process to synthesize muvalaplin, a small-molecule lipoprotein(a) inhibitor for the potential reduction of major adverse cardiovascular events in participants with established cardiovascular disease or at risk for a first cardiovascular event. Each step was optimized, leading to improvements in safety, robustness, and cost of goods that ultimately resulted in a 41% yield increase over three steps and a 60% reduction in PMI compared to the original discovery synthesis. The process was safely scaled to >100 kg, thus ensuring clinical supply and laying the foundation for a commercial route.Keywords
This publication has 31 references indexed in Scilit:
- Oral Muvalaplin for Lowering of Lipoprotein(a)JAMA, 2025
- Zerlasiran—A Small-Interfering RNA Targeting Lipoprotein(a)JAMA, 2024
- Lp(a): A Rapidly Evolving Therapeutic LandscapeCurrent Atherosclerosis Reports, 2024
- Mechanism of the generation of benzaldehyde and benzoic acid on Pd (1 1 1) surface during the destruction of toluene: Verification of experiments and modelsApplied Surface Science, 2024
- Lepodisiran, an Extended-Duration Short Interfering RNA Targeting Lipoprotein(a)JAMA, 2023
- Muvalaplin, an Oral Small Molecule Inhibitor of Lipoprotein(a) FormationJAMA, 2023
- Practical Synthetic Organic Chemistry2020
- Understanding Palladium Acetate from a User PerspectiveChemistry – A European Journal, 2016
- False Results Caused by Solvent Impurity in Tetrahydrofuran for MALDI TOF MS Analysis of AminesJournal of the American Society for Mass Spectrometry, 2013
- A General and Efficient Method for the Formylation of Aryl and Heteroaryl BromidesAngewandte Chemie International Edition, 2005